论文部分内容阅读
目的探讨孟鲁斯特纳对反复发作性过敏性紫癜患者临床疗效、不良反应及复发率的影响。方法选取2015年6月至2016年6月于辽宁阜新市矿务集团总医院接受临床治疗的50例反复发作性过敏性紫癜患者作为研究对象,根据治疗方式不同将其分为对照组和观察组,各25例。对照组患者给予常规治疗,观察组患者在对照组基础上采用孟鲁斯特纳进行治疗,比较两组患者临床疗效、不良反应发生及病情复发情况、尿生化指标。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应发生率及复发率均明显低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者尿中免疫球蛋白G(IgG)、微量白蛋白(Alb)、转铁蛋白(TRF)、β2-微球蛋白(β2-MG)水平均明显低于对照组,差异均有统计学意义(均P<0.05)。结论给予反复发作性过敏性紫癜患者孟鲁斯特纳治疗,能够有效降低不良反应率及复发率,提高临床疗效,改善患者的生命质量。
Objective To investigate the clinical effects, side effects and recurrence rate of Montelukastner on patients with recurrent anaphylactoid purpura. Methods Fifty patients with recurrent anaphylactoid purpura undergoing clinical treatment in Fuxin Mining General Hospital of Liaoning Province from June 2015 to June 2016 were selected as research subjects and divided into control group and observation group according to different treatment methods , 25 cases each. The patients in the control group were given routine treatment. The patients in the observation group were treated with Montelukast in the control group. The clinical efficacy, adverse reactions, recurrence and urinary biochemical indexes were compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). The adverse reaction rate and recurrence rate of observation group were significantly lower than that of control group, the differences were statistically significant (All P <0.05). After treatment, the levels of urinary IgG, Alb, TRF and β2-MG in the observation group were significantly higher than those in the control group Lower than the control group, the difference was statistically significant (P <0.05). Conclusion The treatment of recurrent allergic purpura in patients with Montelukast Turner, can effectively reduce the adverse reaction rate and recurrence rate, improve clinical efficacy and improve the quality of life of patients.